会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • METHOD FOR TREATING VASCULITIS
    • 治疗血管瘤的方法
    • WO2006041680A2
    • 2006-04-20
    • PCT/US2005/034647
    • 2005-09-28
    • GENENTECH, INC.BRUNETTA, Paul G.
    • BRUNETTA, Paul G.
    • C07K16/2887A61K2039/505A61K2039/545C07K2317/24C07K2317/72
    • A method of treating anti-neutrophil cytoplasmic antibodies-associated vasculitis (ANCA-associated vasculitis) in a patient eligible for treatment is provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the patient in a dose of about 400 mg to 1.3 grams at a frequency of one to three doses within a period of about one month. Another method of treating ANCA-associated vasculitis in a subject eligible for treatment is provided involving administering an effective amount of an antibody that binds to a B-cell surface marker to the subject to provide an initial exposure and a subsequent exposure to the antibody within certain dosing regimens. Further provided are articles of manufacture useful for such methods.
    • 提供了一种在符合治疗条件的患者中治疗抗嗜中性粒细胞胞浆抗体相关血管炎(ANCA相关性血管炎)的方法,该方法包括给患者施用结合B细胞表面标志物如CD20抗体的拮抗剂, 在约1个月的时间内,剂量为约400mg至1.3g,频率为1至3次。 提供了治疗有资格治疗的受试者中ANCA相关性血管炎的另一种方法,包括给受试者施用有效量的结合B细胞表面标志物的抗体以提供初始暴露并随后暴露于抗体内 给药方案 还提供了对这种方法有用的制品。
    • 4. 发明申请
    • METHOD FOR TREATING VASCULITIS
    • 治疗血管瘤的方法
    • WO2006041680A3
    • 2007-08-23
    • PCT/US2005034647
    • 2005-09-28
    • GENENTECH INCBRUNETTA PAUL G
    • BRUNETTA PAUL G
    • C07K16/28
    • C07K16/2887A61K2039/505A61K2039/545C07K2317/24C07K2317/72
    • A method of treating anti-neutrophil cytoplasmic antibodies-associated vasculitis (ANCA-associated vasculitis) in a patient eligible for treatment is provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the patient in a dose of about 400 mg to 1.3 grams at a frequency of one to three doses within a period of about one month. Another method of treating ANCA-associated vasculitis in a subject eligible for treatment is provided involving administering an effective amount of an antibody that binds to a B-cell surface marker to the subject to provide an initial exposure and a subsequent exposure to the antibody within certain dosing regimens. Further provided are articles of manufacture useful for such methods.
    • 提供了一种在符合治疗条件的患者中治疗抗嗜中性粒细胞胞质抗体相关血管炎(ANCA相关性血管炎)的方法,包括在患者中给予患者结合B细胞表面标志物如CD20抗体的拮抗剂 在约1个月的时间内以1-3剂量的剂量约400mg至1.3g的剂量。 提供了治疗有资格治疗的受试者中ANCA相关血管炎的另一种方法,包括将有效量的结合B细胞表面标志物的抗体施用于受试者以提供初始暴露,并随后暴露于抗体内 给药方案 还提供了对这种方法有用的制品。